

The Association of Silymarin, Vitamin C, Vitamin E, Coenzyme Q10 and Selenomethionine for the Treatment of Non Alcoholic Fatty Liver Disease

Adriana Romano¹, Annalisa Curcio¹, Antonio Di Nicola², Orazio Grassi², Donatella Schiaroli³, Giuseppe Fabrizio Nocera⁴ and Michele Pironti^{1*}

¹*Mercurio Pharma, Naples, Italy*

2

	Medronys epato group® (n=80)			Placebo group (n=71)		
	T0 (Baseline)	T1 (45days)	T2(90 days)	T0 (Baseline)	T1 (45 days)	T2 (90 days) P value
Markers of liver damage - mean (± SD)						
ALT, U/L	71.6 (± 31.8)	52 (± 24.4)	39.4 (± 14.6)	82.4 (± 18.2)	83.6 (± 18.1)	78.7 (± 17.8)
AST, U/L	64 (± 30.4)	45.7 (± 21.2)	32.7 (± 11.4)	60.4 (± 10.5)	61.1 (± 10.2)	56.55 (± 10.3)
ALP, U/L	104.7 (± 13.2)	87.6 (± 53)	81.3 (± 54.8)	87.2 (± 12.9)	85.9 (± 3.8)	83.6 (± 13.6)
GGT, U/L	116.0 (± 17)	85.7 (± 24)	71.0 (± 29)	49.7 (± 9.2)	51.4 (± 9.2)	46.08 (± 8.7)
Ferritin, µg/L	116.0 (± 13)	105.4 (± 11)	93.6 (± 10)	234.5 (± 22)	346 (± 11.2)	340 (± 13.1)

Data are expressed as mean (± SD); ALT: Alanine Amino Transferase; AST: Aspartate Amino Transferase; ALP: Alkaline Phosphatase; GGT: Gamma-Glutamyl Transpeptidase; p value < 0.001, Medronys epato at T1 and T2 vs T0 (baseline); p value > 0.05, placebo at T1 and T2 vs T0 (baseline); a p value less than 0.05 is considered statistically significant.

Patient judgment

At the end of the treatment (90 days) with Medronys epato[®], we asked to the patients if they had obtained from the treatment and of which entity. parameters used were: a) no b) real and c) great

data were collected for all the patients (151). 96% of patients in Medronys epato[®] group reported an improvement of symptoms treatment with Medronys epato[®].

In details, in Medronys epato[®] group, 3 patients (4%) reported that they had no by treatment, 52 patients (65%) reported a real and 25 patients (31%) reported a great bn